Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Formycon Submits Eylea Biosimilar For European Approval Following Strong Q3

Revenue Increased 113% During First Nine Months Of 2023

Executive Summary

Formycon has submitted its aflibercept candidate for European Medicines Agency consideration, following an incredibly strong Q3 which has put the company on track for a promising future.

You may also be interested in...

Gedeon Richter Investment In Formycon Opens Up Collaboration Opportunities

Gedeon Richter has agreed to acquire a stake of just over 9% in Formycon. The deal “opens up the possibility of jointly leveraging long-term strategic opportunities” while providing Formycon with more than €80m to invest in its biosimilar development projects.

Formycon Believes Itself Among Frontrunners For Mammoth Keytruda Opportunity

On the back of early success with its biosimilar to Lucentis (ranibizumab), Formycon has looked further into the future and divulged details on the set-to-be competitive race to develop a biosimilar to Merck & Co’s 10bn ($10.9bn) PD-1 inhibitor Keytruda (pembrolizumab).

Xbrane Drops Keytruda Rival As It Pares Down Pipeline And Personnel

Swedish biosimilars developer Xbrane Biopharma has revealed that it is dropping development of its planned Xtrudane pembrolizumab biosimilar to Keytruda, as part of a move towards a more “focused development portfolio.” At the same time, the firm has announced job cuts as part of a new cost-savings scheme designed to help the firm “achieve a positive cash flow as soon as possible.”

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts